267 related articles for article (PubMed ID: 18055314)
1. [Interim analyses].
Kramar A; Paoletti X
Bull Cancer; 2007 Nov; 94(11):965-74. PubMed ID: 18055314
[TBL] [Abstract][Full Text] [Related]
2. The Children's Oncology Group routinely applies "lack of efficacy" interim monitoring to its randomized clinical trials.
Anderson JR; Krailo M
Am J Bioeth; 2011 Mar; 11(3):18-9. PubMed ID: 21400379
[No Abstract] [Full Text] [Related]
3. Design of randomized controlled trials.
Stanley K
Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
[No Abstract] [Full Text] [Related]
4. Methodology of superiority vs. equivalence trials and non-inferiority trials.
Christensen E
J Hepatol; 2007 May; 46(5):947-54. PubMed ID: 17412447
[TBL] [Abstract][Full Text] [Related]
5. Group-sequential methods for adaptive seamless phase II/III clinical trials.
Stallard N
J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
[TBL] [Abstract][Full Text] [Related]
6. Monitoring clinical trials: issues and controversies regarding confidentiality.
Fleming TR; Ellenberg S; DeMets DL
Stat Med; 2002 Oct; 21(19):2843-51. PubMed ID: 12325100
[TBL] [Abstract][Full Text] [Related]
7. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.
Korn EL; Freidlin B
Am J Bioeth; 2011 Mar; 11(3):2-10. PubMed ID: 21400374
[TBL] [Abstract][Full Text] [Related]
8. The prevalence of underpowered randomized clinical trials in rheumatology.
Keen HI; Pile K; Hill CL
J Rheumatol; 2005 Nov; 32(11):2083-8. PubMed ID: 16265683
[TBL] [Abstract][Full Text] [Related]
9. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?
Ellenberg SS; George SL
Stat Med; 2004 May; 23(10):1503-5. PubMed ID: 15122727
[TBL] [Abstract][Full Text] [Related]
10. Current controversies in data monitoring for clinical trials.
Pocock SJ
Clin Trials; 2006; 3(6):513-21. PubMed ID: 17170035
[TBL] [Abstract][Full Text] [Related]
11. What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting?
Bryant J
Stat Med; 2004 May; 23(10):1507-11. PubMed ID: 15122728
[TBL] [Abstract][Full Text] [Related]
12. Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment.
Whitehead J; Matsushita T
Stat Med; 2003 Mar; 22(5):677-87. PubMed ID: 12587099
[TBL] [Abstract][Full Text] [Related]
13. Incorporating intermediate binary responses into interim analyses of clinical trials: a comparison of four methods.
Whitehead A; Sooriyarachchi MR; Whitehead J; Bolland K
Stat Med; 2008 May; 27(10):1646-66. PubMed ID: 17886243
[TBL] [Abstract][Full Text] [Related]
14. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
15. The independent statistician for data monitoring committees.
DeMets DL; Fleming TR
Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729
[TBL] [Abstract][Full Text] [Related]
16. Sample size estimation in phase III cancer clinical trials.
Curran D; Sylvester RJ; Hoctin Boes G
Eur J Surg Oncol; 1999 Jun; 25(3):244-50. PubMed ID: 10336801
[TBL] [Abstract][Full Text] [Related]
17. Data monitoring committees, interim analysis and early termination in paediatric trials.
Fernandes RM; van der Lee JH; Offringa M
Acta Paediatr; 2011 Oct; 100(10):1386-92. PubMed ID: 21434998
[TBL] [Abstract][Full Text] [Related]
18. Design, operation, and interpretation of clinical trials.
Pihlstrom BL; Barnett ML
J Dent Res; 2010 Aug; 89(8):759-72. PubMed ID: 20581353
[TBL] [Abstract][Full Text] [Related]
19. Futility approaches to interim monitoring by data monitoring committees.
Demets DL
Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
[TBL] [Abstract][Full Text] [Related]
20. Designing phase III or IV trials for vaccines: choosing between individual or cluster randomised trial designs.
Vaucher P
Vaccine; 2009 Mar; 27(13):1928-31. PubMed ID: 19368773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
